Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Cbd5.8
CBD – Forschung
Überwiegend Mechanismus / Beobachtung
46 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu CBD sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2017–2026 mit einer typischen Studiengröße von 120 Teilnehmenden.
Basierend auf 46 Studien · 10 Meta-Analysen · 12 RCTs · 56,347 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Anxiety & stressKann Angstzustände reduzieren; die Evidenz ist vielversprechend, aber begrenzt und von geringerer Qualität (kein Ersatz für erprobte Behandlungen) · Akut-4 Wochen
Überwiegend Mechanismus / Beobachtung6 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung6 Studien
Cognitive function
Überwiegend Mechanismus / Beobachtung5 Studien
Therapeutic & clinical
Überwiegend Mechanismus / Beobachtung5 Studien
InflammationEntzündungshemmende Wirkungen werden postuliert; die Evidenz beim Menschen ist begrenzt · 2-8 Wochen
Überwiegend Mechanismus / Beobachtung3 Studien
Pain & analgesia
Überwiegend Mechanismus / Beobachtung3 Studien
Sleep & insomniaWird häufig zur Schlafförderung verwendet, doch eine kontrollierte Studie zeigte, dass niedrig dosiertes CBD bei Schlafparametern nicht besser als Placebo war · Akut
Zu wenige bewertete Studien2 Studien
Glucose & metabolic
Zu wenige bewertete Studien2 Studien
6 weitere Outcomes mit weniger Studien nicht angezeigt.
Aktives Forschungsgebiet
40 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
20172026
1RCTn=120 · medium study2017
In the pivotal Dravet-syndrome trial (NEJM), cannabidiol reduced convulsive-seizure frequency more than placebo (the basis for FDA-approved Epidiolex).
Devinsky O et al. · The New England journal of medicine (2017)
Convulsive seizures fell from 12.4 to 5.9/month with CBD vs 14.9 to 14.1 with placebo
Higher rate of adverse events (somnolence, diarrhea, liver enzymes)
High-dose prescription CBD, not OTC wellness doses
Cannabinoid use is associated with concurrent pro- and anti-inflammatory modulation in non-medical populations, consistent with immunomodulatory effects rather than a uniform pro- or anti-inflammatory shift.
Belvederi Murri M et al. · Brain, behavior, and immunity (2026)
We included 46 studies (54,382 participants); 190 effect sizes from 40 studies were pooled in three meta-analyses (n = 178 effects from cross-sectional and case-control studies, n = 2 prospective studies, n = 10 RCTs).
RCTs of cannabidiol suggested small increase of pro-inflammatory markers (SMD 0.15; 95% CrI, -0.07 to 0.36; PD 90.9%).
Cannabinoid use is associated with concurrent pro- and anti-inflammatory modulation in non-medical populations, consistent with immunomodulatory effects rather than a uniform pro- or anti-inflammatory shift.
The current evidence base is not sufficient to support the use of cannabis for the treatment of mental health conditions and demonstrates substantial risks of adverse effects.
Kansagara D et al. · JAMA internal medicine (2026)
The current evidence base is not sufficient to support the use of cannabis for the treatment of mental health conditions and demonstrates substantial risks of adverse effects.
Clinicians should engage patients with mental health conditions in discussions about cannabis use because use is common, has an influence on mental health symptoms, and is likely an important modifiable risk factor for mental health conditions in some populations.
Determining CBD's full therapeutic potential in AD necessitates future rigorous, mechanism-driven trials with standardized preparations and biomarker-anchored endpoints.
Wu S, Rajiah T, Ali AB. · International journal of molecular sciences (2025)
In preclinical AD models, the meta-analysis demonstrated that CBD significantly and consistently reduced key markers of neuroinflammation and reactive gliosis, specifically glial fibrillary acidic protein (GFAP) ( p < 0.0001), Interleukin-6 (IL-6), and inducible nitric oxide synthase (iNOS).
Clinical evidence, though limited by small sample size and heterogeneity, showed a borderline significant benefit favoring CBD for overall behavioral symptoms ( p = 0.05), agitation, and caregiver distress.
A systematic review/meta-analysis found cannabidiol use was associated with markedly higher odds of liver-enzyme elevation and drug-induced liver injury.
Lo LA et al. · Journal of internal medicine (2023)
Liver-enzyme elevation OR 5.85 vs placebo (p<0.001)
Drug-induced liver injury OR 4.82
Risk higher at high doses and with concomitant valproate
Conclusions Cannabidiol use appears to be more prevalent in North America compared with Europe.
Weidberg S, Iza-Fernández C, Alemán-Moussa L, Krotter A, González-Roz A. · Addiction (Abingdon, England) (2026)
A total of 43 studies (48 distinct samples; n = 388 447; 57.52% female) from North America (k = 30; n = 353 088) and Europe (k = 13; n = 35 359) were included in the analyses.
In Europe, the pooled lifetime prevalence of CBD use was 12.8% [95% confidence interval (CI) = 0.06-0.25], 17.6% (95% CI = 0.11-0.28) in the past 12 months, 7.2% (95% CI = 0.02-0.21) in the past month, 4.3% (95% CI = 0.01-0.13) in the past week and 2.1% (95% CI = 0.01-0.08) daily.
In North America, lifetime pooled estimates were 28.9% (95% CI = 0.2-0.39), 19.5% in the past 12 months (95% CI = 0.11-0.32), 12% in the past month (95% CI = 0.07-0.2), 10.5% in the past week (95% CI = 0.01-0.47) and 6.4% daily (95% CI = 0.03-0.13).
While these findings support its therapeutic potential and provide a rationale for guiding translational research, clinical evidence in humans is still limited and inconclusive, underscoring the need for further research.
Jantsch J, Wickert F, Fraga GF, de Fraga LS, Durán-Carabali LE, Guedes RP. · Molecular psychiatry (2026)
Results CBD consistently reduced anxiety- and depressive-like behaviors, with moderate effect sizes observed in paradigms such as the elevated plus maze, novelty suppressed feeding, forced swim, sucrose preference, and tail suspension test.
Mechanistic evidence implicates serotonergic signaling (notably 5-HT1A receptors), endocannabinoid modulation, anti-inflammatory and neurotrophic pathways, as well as mitochondrial and synaptic plasticity processes, as contributors to these behavioral outcomes.
Risk of bias assessment indicated moderate to high quality across studies, confirming the robustness of the findings.
Finally, these perspectives are integrated to provide guidance for reducing variability and improving clinical translation in CBD research.
Bidwell LC, Vandrey R. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2026)
Evidence for its safety and efficacy comes from a variety of sources, including preclinical studies, clinical trials, and observational studies of real-world evidence.
The challenge in interpreting these data is that CBD products are diverse with respect to format, formulation, intended route of administration, dose, and regulatory oversight with regard to quality assurance and labeling.
Finally, these perspectives are integrated to provide guidance for reducing variability and improving clinical translation in CBD research.
Mechanistically informed trials of novel compounds, including next-generation CB-1R antagonists and CBD, are needed to bridge this translational gap and yield new treatments for AUD.
Costa GPA, Cerezo-Matias MA, Funaro MC, Bagdas D, Kaye A, Krystal J, Petrakis I, De Aquino JP. · Molecular psychiatry (2026)
Preclinical data meta-analyses demonstrated that CB-1R inverse agonists (SMD = -1.21) and CBD (SMD = -0.70) reduced alcohol intake, while CB-1R agonists increased consumption (SMD = +0.66).
Dose-response analyses identified non-linear effects for CB-1R inverse agonists and CBD.
In contrast, human studies showed inconsistent and generally null effects, with limited studies examining newer ECS modulators beyond rimonabant or CBD.
This article provides an analysis of the mechanisms by which the EC system, and more specifically the CB1 receptor, influences skeletal muscle development and function, while exploring emerging data on the potential benefits of CBD in various pathological conditions affecting skeletal muscle.
Deglos A, Saroul N, Walrand S, Le Bacquer O. · Molecular metabolism (2026)
Present in many peripheral tissues, including skeletal muscle, EC system is now recognized to influence key physiological processes such as insulin sensitivity, mitochondrial metabolism, protein homeostasis and muscle development.
Alterations in this system are associated with a variety of pathologies, including obesity, type 2 diabetes, sarcopenia, cachexia and muscle dystrophies.
In this context, cannabidiol (CBD), a phytocannabinoid devoid of psychoactive properties, is attracting growing interest as a potential therapeutic agent.
Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
Rosa L, Lisano JK, Skrzynski CJ, Bryan AD, Bidwell LC. · International journal of environmental research and public health (2026)
Anxiety significantly decreased over the study period in both flower and edibles groups.
In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%).
In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days.
Finally, the remaining challenges associated with the clinical application of CBD and future development directions are discussed.
Han B, Zhang Y, Wang Y, Shen Y, Niu J, Li S, Li Y, Wang J, Ma X, Zheng W. · Pharmaceutics (2026)
This review first summarizes the relationship between CBD and the mucosal endocannabinoid system, together with its pharmacological effects.
It then discusses the therapeutic potential of CBD in mucosal disorders of the digestive and respiratory systems.
In addition, current administration routes and advanced delivery systems for CBD are reviewed to provide insights for future research and clinical translation.
GPR3 acts as a central molecular hub integrating neural, metabolic, immune, and reproductive signaling, highlighting its potential as a therapeutic target for chronic multisystem disorders.
Feng BD et al. · Annals of medicine (2026)
GPR3 acts as a central molecular hub integrating neural, metabolic, immune, and reproductive signaling, highlighting its potential as a therapeutic target for chronic multisystem disorders.
However, its dual roles in certain pathologies and translation challenges necessitate further research.
This review underscores the urgent need for future research to prioritize long-term evaluations, explore synergistic CBD-drug combinations, develop advanced CBD delivery systems, and assess its dual role in tumor suppression and pain management to enable clinical use.
Feng X et al. · Biochemical pharmacology (2026)
Despite its therapeutic promise, the clinical translation of CBD faces key hurdles, including poorly characterized mechanisms of EV regulation in OSCC, a lack of targeted delivery systems that compromises specificity and bioavailability, and a general scarcity of OSCC-specific evidence.
This review underscores the urgent need for future research to prioritize long-term evaluations, explore synergistic CBD-drug combinations, develop advanced CBD delivery systems, and assess its dual role in tumor suppression and pain management to enable clinical use.
This review highlights the need for methodologically rigorous and transparent clinical studies, standardised formulations, validated outcome measures and the integration of sustainability metrics to strengthen evidence synthesis, clarify clinical relevance and guide responsible cosmeceutical development.
Komane B, Kaye T. · Molecules (Basel, Switzerland) (2026)
Lipid-rich hemp seed-derived products were considered only in a contextual capacity for barrier-supportive and nutritional properties and were excluded from efficacy synthesis unless cannabinoid content was verified.
Overall, CBD-containing hemp extracts show biologically plausible and clinically promising adjunctive potential for mild-to-moderate inflammatory acne, but current evidence remains preliminary.